[Antiischemic efficacy of trimetazidine in patients with intermittent claudication and effort angina]

Related Experiment Video

Updated: Sep 20, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

A L Syrkin1, E G Artiukhina, S G Kanorskiĭ

  • 1Moskovskaia meditsinskaia akademiia im. I. M. Sechenova, Moskva.

Kardiologiia
|August 2, 2003
PubMed

Insights

Adding trimetazidine to simvastatin and clopidogrel significantly improved outcomes for male patients with peripheral artery disease and angina. This combination therapy reduced angina attacks and increased walking distance.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Atherosclerosis obliterans (AO) and peripheral artery disease (PAD) significantly impact lower extremity circulation.
  • Concurrent angina pectoris exacerbates cardiovascular risk in patients with PAD.
  • Current treatments often focus on single-pathway interventions.

Purpose of the Study:

  • To evaluate the efficacy of adding trimetazidine to standard therapy for patients with AO and angina.
  • To assess the impact on angina symptoms, medication use, and functional capacity.

Main Methods:

  • A randomized controlled trial involving 42 male patients with AO (Stage IIA-III ischemia) and angina (Class II-III).
  • Group 1 (n=21) received simvastatin, clopidogrel, and trimetazidine for 6 months.
  • Group 2 (n=21) received simvastatin and clopidogrel for 6 months.

Main Results:

  • Group 1 demonstrated statistically significant reductions in angina attack frequency.
  • Group 1 showed a significant decrease in nitroglycerin consumption.
  • Patients in Group 1 experienced a significant increase in walking distance compared to Group 2.

Conclusions:

  • Trimetazidine, when added to simvastatin and clopidogrel, offers significant benefits for patients with PAD and angina.
  • This combination therapy improves angina control and enhances peripheral circulation and functional capacity.
  • Trimetazidine represents a valuable therapeutic option for managing complex cardiovascular conditions involving PAD and ischemic heart disease.

More Related Videos

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...